Qiagen N.V. has engaged advisers to explore a range of strategic options for its diagnostics business following renewed takeover interest from multiple potential acquirers, people with direct knowledge told Bloomberg. The review encompasses a potential sale of the diagnostics unit, joint-venture partnerships and minority stake investments. The diagnostics segment contributed approximately 40% of Qiagen’s total revenues in the first nine months of 2025, serving more than 500,000 customers worldwide. With a workforce of around 5,700 employees across over 35 locations, Qiagen aims to maximize shareholder value by assessing offers that reflect the unit’s strong market position in sample-to-insight solutions for clinical laboratories and molecular diagnostics applications. Qiagen will publish its fourth-quarter 2025 financial results on February 4, shortly after 22:05 Frankfurt time (21:05 London, 16:05 New York). A webcast and conference call will follow on February 5 at 15:30 Frankfurt time (14:30 London, 09:30 New York), providing commentary from the executive team on performance metrics, including margin improvement targets and capital allocation plans. Participants can register for a call-back connection, dial in via dedicated U.S., U.K. or German numbers using Conference ID 3382302, or access the live audio webcast through the company’s investor relations portal. A replay of the call will be available online immediately after the event, allowing investors to review discussions on strategic initiatives, R&D investment in bioinformatics platforms and expected revenue contributions from recently launched automation solutions.